Epigral Stock Falls to 52-Week Low of Rs.1428 Amidst Sector Underperformance

Intraday Price Movement and Market Context

On 24 Nov 2025, Epigral's share price touched an intraday low of Rs.1428, representing a decline of 2.08% for the day. This performance contrasts with the broader market, where the Sensex opened 88.12 points higher and was trading at 85,343.57, up 0.13%. The Sensex remains close to its 52-week high of 85,801.70, just 0.54% away, supported by mega-cap stocks leading the gains. Additionally, the Sensex has recorded a 2.56% rise over the past three weeks, trading above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a bullish trend for the benchmark index.

In contrast, Epigral has underperformed its sector by 0.85% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating sustained downward pressure on the stock price.

Long-Term and Recent Performance Metrics

Over the last year, Epigral's stock has recorded a return of -26.32%, significantly lagging behind the Sensex's 7.85% gain during the same period. The stock's 52-week high was Rs.2195.85, highlighting the extent of the decline to the current low.

Examining the company's financial performance, operating profit has shown a compound annual decline of 5.49% over the past five years. The most recent quarterly results reveal a mixed picture: operating profit to net sales ratio stands at a low 22.53%, while profit after tax (PAT) for the quarter was Rs.51.22 crores, reflecting a fall of 52.6% compared to the previous four-quarter average. Meanwhile, interest expenses for the latest six months have risen sharply to Rs.45.21 crores, a growth of 286.41%.

Comparative Sector and Valuation Insights

Despite the recent price weakness, Epigral exhibits certain strengths in management efficiency and financial health. The company reports a return on capital employed (ROCE) of 23.19%, indicating effective utilisation of capital. Its debt servicing capability is supported by a low Debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels.

Valuation metrics show an enterprise value to capital employed ratio of 2.6, which is considered fair relative to peers. The stock is trading at a discount compared to the average historical valuations of its sector counterparts. Over the past year, while the stock price has declined by 26.32%, the company's profits have risen by 37.1%, resulting in a price/earnings to growth (PEG) ratio of 0.5.

Shareholding and Market Position

Epigral's majority shareholding rests with promoters, maintaining a stable ownership structure. The company operates within the Specialty Chemicals industry, a sector that has seen mixed performance in recent months.

Summary of Key Financial Indicators

To summarise, Epigral's recent stock price movement to Rs.1428 marks a significant 52-week low, reflecting a period of subdued performance relative to the broader market and its sector. The company’s financial data reveals a decline in operating profit margins and PAT in the latest quarter, alongside a notable rise in interest expenses. However, the firm maintains strong capital efficiency and manageable debt levels, with valuation metrics indicating a discount relative to peers.

While the Sensex and mega-cap stocks have shown resilience and upward momentum, Epigral’s share price remains under pressure, trading below all key moving averages and continuing a downward trend over the past year.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →